ASHP COVID-19 Resource Center
ASHP is committed to supporting you in the response to the COVID-19 pandemic and is regularly communicating updates on this crisis. We have opened access to our evidence-based online resources and tools on ashp.org, making them widely available to all pharmacists and healthcare professionals, and ourCOVID-19 Resource Centeris updated frequently. ASHP has also launched a newCOVID-19 Community on Connect, which serves as a forum for any healthcare providers to ask questions, share experiences, post resources, and more. Thank you for all that you are doing for your patients and your community.
Open Access To ASHP's Interactive Handbook On Injectable Drugs
In response to the rapidly increasing use of parenteral medications needed for the critical care of patients with COVID-19, ASHP is providing free access to theInteractive Handbook on Injectable Drugs.
The Interactive Handbook on Injectable Drugs has monographs for 400 parenteral medications including sedatives, neuromuscular blockers, opioids, and vasopressors. Users can search compatibility results for drugs and solutions under the Compatibility Tab. For additional details, use the Monograph Tab to locate information on:
- Solution concentrations
- Extended stability (when available)
Access ASHP's Interactive Handbook on Injectable Drugs.
Additionally, ASHP has also opened access to our evidence-based online drug information tool, AHFS Clinical Drug Information®. AHFS CDI is available with theusername: email@example.com: covid-19.
ASHP's patient medication information is available atwww.safemedication.com.
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
JAMA | Review - Published online April 13, 2020 [Abstract Below]
ImportanceThe pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.
ObservationsNo proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.
Conclusions and RelevanceThe COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.